1. Sanders, B., Koldijk, M., and Schuitemaker, H., Inactivated viral vaccines, Vaccine Analysis: Strategies, Principles, and Control, Berlin: Springer-Verlag, 2015, pp. 45—80.
2. Lawrence, S.A., Beta-propiolactone: viral inactivation in vaccines and plasma products, PDA J. Pharm Sci. Technol., 2000, vol. 54, pp. 209—214.
3. Kurashova, S.S., Ishmukhametov, A.A., Egorova, M.S., et al., Comparative characteristics of inactivating agents for the development of a vaccine against hemorrhagic fever with renal syndrome, Epidemiol. Vaktsinoprofil., 2018, vol. 17, no. 4, pp. 26—29. https://doi.org/10.31631/2073-3046-2018-17-4-26-29
4. Colburn, N.H., Richardson, R.G., and Boutwell, R.K., Studies of the reaction of β-propiolactone with deoxyguanosine and related compounds, Biochem. Pharmacol., 1965, vol. 14, pp. 1113—1118.
5. β-Propiolactone, in IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Lion: IARC, 1999, vol. 71, pp. 1103—1118.